Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial

What is it about?

Article summary Strengths and limitations of this study - This is a pilot trial that will inform the design of a larger trial comparing rituximab versus standard care in MN with heavy proteinuria (>3.5 g/24 hours); being a pilot study, this study will not address intervention questions. - Complete remission of proteinuria (primary end-point) is a clinically important and more frequent outcome than kidney failure (final outcome). A trial looking at kidney failure for outcome may not be feasible. - Recruitment potential of a trial comparing rituximab to cyclophosphamide is unknown; we will provide preliminary estimates and reasons for exclusion which may be used to increase the feasibility of a larger study

Featured Image